Logo image of BLIN

BRIDGELINE DIGITAL INC (BLIN) Stock Fundamental Analysis

NASDAQ:BLIN - Nasdaq - US10807Q7007 - Common Stock - Currency: USD

1.43  +0.04 (+2.88%)

After market: 1.49 +0.06 (+4.2%)

Fundamental Rating

2

Taking everything into account, BLIN scores 2 out of 10 in our fundamental rating. BLIN was compared to 281 industry peers in the Software industry. BLIN may be in some trouble as it scores bad on both profitability and health. BLIN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BLIN had negative earnings in the past year.
BLIN had a positive operating cash flow in the past year.
In the past 5 years BLIN reported 4 times negative net income.
In the past 5 years BLIN reported 4 times negative operating cash flow.
BLIN Yearly Net Income VS EBIT VS OCF VS FCFBLIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

BLIN's Return On Assets of -12.69% is on the low side compared to the rest of the industry. BLIN is outperformed by 62.90% of its industry peers.
BLIN's Return On Equity of -20.66% is in line compared to the rest of the industry. BLIN outperforms 44.17% of its industry peers.
Industry RankSector Rank
ROA -12.69%
ROE -20.66%
ROIC N/A
ROA(3y)-19.42%
ROA(5y)-20.55%
ROE(3y)-30.45%
ROE(5y)-37.76%
ROIC(3y)N/A
ROIC(5y)N/A
BLIN Yearly ROA, ROE, ROICBLIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

BLIN has a Gross Margin of 67.67%. This is comparable to the rest of the industry: BLIN outperforms 51.24% of its industry peers.
In the last couple of years the Gross Margin of BLIN has grown nicely.
The Profit Margin and Operating Margin are not available for BLIN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.05%
GM growth 5Y8.05%
BLIN Yearly Profit, Operating, Gross MarginsBLIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

3

2. Health

2.1 Basic Checks

BLIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BLIN remains at a similar level compared to 1 year ago.
BLIN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BLIN has an improved debt to assets ratio.
BLIN Yearly Shares OutstandingBLIN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
BLIN Yearly Total Debt VS Total AssetsBLIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

BLIN has an Altman-Z score of -6.33. This is a bad value and indicates that BLIN is not financially healthy and even has some risk of bankruptcy.
BLIN has a worse Altman-Z score (-6.33) than 83.75% of its industry peers.
The Debt to FCF ratio of BLIN is 1.49, which is an excellent value as it means it would take BLIN, only 1.49 years of fcf income to pay off all of its debts.
BLIN has a better Debt to FCF ratio (1.49) than 68.20% of its industry peers.
BLIN has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, BLIN is in the better half of the industry, outperforming 62.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 1.49
Altman-Z -6.33
ROIC/WACCN/A
WACC13.84%
BLIN Yearly LT Debt VS Equity VS FCFBLIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M

2.3 Liquidity

BLIN has a Current Ratio of 0.62. This is a bad value and indicates that BLIN is not financially healthy enough and could expect problems in meeting its short term obligations.
BLIN's Current ratio of 0.62 is on the low side compared to the rest of the industry. BLIN is outperformed by 87.99% of its industry peers.
A Quick Ratio of 0.62 indicates that BLIN may have some problems paying its short term obligations.
The Quick ratio of BLIN (0.62) is worse than 87.63% of its industry peers.
Industry RankSector Rank
Current Ratio 0.62
Quick Ratio 0.62
BLIN Yearly Current Assets VS Current LiabilitesBLIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

BLIN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.32%, which is quite impressive.
The Revenue has decreased by -1.02% in the past year.
The Revenue has been growing by 9.07% on average over the past years. This is quite good.
EPS 1Y (TTM)26.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-1.02%
Revenue growth 3Y5.02%
Revenue growth 5Y9.07%
Sales Q2Q%0.96%

3.2 Future

BLIN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.92% yearly.
The Revenue is expected to grow by 6.33% on average over the next years.
EPS Next Y-53%
EPS Next 2Y-5.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.69%
Revenue Next 2Y6.33%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BLIN Yearly Revenue VS EstimatesBLIN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
BLIN Yearly EPS VS EstimatesBLIN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BLIN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BLIN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLIN Price Earnings VS Forward Price EarningsBLIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

BLIN's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 54.29
EV/EBITDA N/A
BLIN Per share dataBLIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

BLIN's earnings are expected to decrease with -5.92% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.92%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BLIN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIDGELINE DIGITAL INC

NASDAQ:BLIN (3/7/2025, 8:07:54 PM)

After market: 1.49 +0.06 (+4.2%)

1.43

+0.04 (+2.88%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-14 2025-02-14/bmo
Earnings (Next)05-12 2025-05-12
Inst Owners4.23%
Inst Owner Change7.57%
Ins Owners20.18%
Ins Owner Change0.72%
Market Cap14.93M
Analysts80
Price Target2.81 (96.5%)
Short Float %0.83%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.22
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.96%
Min EPS beat(2)-17.65%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)24.84%
Min EPS beat(4)-17.65%
Max EPS beat(4)60.78%
EPS beat(8)5
Avg EPS beat(8)17.68%
EPS beat(12)8
Avg EPS beat(12)38.99%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.39%
Min Revenue beat(2)-4.7%
Max Revenue beat(2)-2.08%
Revenue beat(4)1
Avg Revenue beat(4)-3.71%
Min Revenue beat(4)-11.7%
Max Revenue beat(4)3.63%
Revenue beat(8)1
Avg Revenue beat(8)-3.18%
Revenue beat(12)1
Avg Revenue beat(12)-3.18%
Revenue beat(16)4
Avg Revenue beat(16)-1.94%
PT rev (1m)6.45%
PT rev (3m)28.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)0.15%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)-0.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.97
P/FCF 54.29
P/OCF 48.31
P/B 1.56
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)0.03
FCFY1.84%
OCF(TTM)0.03
OCFY2.07%
SpS1.47
BVpS0.91
TBVpS-0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.69%
ROE -20.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.67%
FCFM 1.79%
ROA(3y)-19.42%
ROA(5y)-20.55%
ROE(3y)-30.45%
ROE(5y)-37.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.05%
GM growth 5Y8.05%
F-Score5
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 1.49
Debt/EBITDA N/A
Cap/Depr 3.69%
Cap/Sales 0.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.62
Quick Ratio 0.62
Altman-Z -6.33
F-Score5
WACC13.84%
ROIC/WACCN/A
Cap/Depr(3y)5.55%
Cap/Depr(5y)5.16%
Cap/Sales(3y)0.51%
Cap/Sales(5y)0.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y-53%
EPS Next 2Y-5.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.02%
Revenue growth 3Y5.02%
Revenue growth 5Y9.07%
Sales Q2Q%0.96%
Revenue Next Year5.69%
Revenue Next 2Y6.33%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year90.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y162.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y206.55%
OCF growth 3YN/A
OCF growth 5YN/A